# Vitae Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vitae-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Fort Washington, US
- Website: www.vitaepharma.com
- Total disclosed funding: $109M
- Latest round: Series D (Oct 29, 2007)
- Investors on record: 7

## About

Founded in 2001 and absed in For Washington, Pennsylvania, Vitae Pharmaceuticals, Inc.operates as a clinical-stage biopharmaceutical company, developing small molecule drugs for the treatment of autoimmune disorders such as psoriasis and atopic dermatitis.

## Funding rounds

- Series D, Oct 29, 2007, $15M — Atlas Venture, New Enterprise Associates, Prospect Venture Partners, Venrock
- Series C, Jul 14, 2005, $15M — Atlas Venture, New Enterprise Associates, Prospect Venture Partners, Wellcome Trust, Venrock, GlaxoSmithKline Plc
- Series B, Jan 4, 2005, $34M — Atlas Venture, New Enterprise Associates, Prospect Venture Partners, Wellcome Trust, Venrock
- Series B, Jan 12, 2004, $15M — New Enterprise Associates, Prospect Venture Partners, Intel Capital, Venrock
- Series B, Aug 6, 2003, $14M — Prospect Venture Partners
- Series A, Jan 1, 2001, $16M — New Enterprise Associates, Prospect Venture Partners, Venrock

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C, Series D
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A, Series B, Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series D
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B, Series C, Series D
- Wellcome Trust — Series B, Series C
- GlaxoSmithKline Plc — Series C